Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

•Contemporary data on outcomes of allogeneic hematopoietic cell transplant (HCT) for T cell acute lymphoblastic leukemia (T-ALL) are limited.•Overall survival after HCT at 5 years for T-ALL was 34%. The corresponding cumulative incidences of nonrelapse mortality and relapse were 26% and 41%, respectively.•In multivariable analysis, factors significantly associated with overall survival were the use of total body irradiation (hazard ratio [HR], 0.57; P = .02); age >35 years (HR, 1.55; P = .025), and relapsed/refractory disease status at transplantation (HR, 1.98; P = .005).•Allogeneic HCT remains a potentially curative option in selected patients with T-ALL; however, relapse remains the major cause of treatment failure.